ConductScience.org, home

Paper41801147

Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial.

Morgan DR and 11 others. Cancer Prev Res (Phila), 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial. Papers, record 41801147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41801147

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial.
PubMed
Journal
Cancer Prev Res (Phila)
PubMed
Year
2026
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-22
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Stomach NeoplasmsMajor topic
Helicobacter InfectionsMajor topic
Precancerous ConditionsMajor topic
EflornithineMajor topic
Humans
Female
Middle Aged
Double-Blind Method
Adult
Helicobacter pylori
Male
Aged
Metaplasia
Follow-Up Studies

Source PubMed

Download CSV of topics

Grants25

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P01 CA028842NCI NIH HHSUnited StatesP01CA028842PubMedNIH RePORTER
5S21MD000242National Institute on Minority Health and Health Disparities (NIMHD)S21MD000242PubMedNIH RePORTER
I01 CX002473CSRD VAUnited StatesI01CX002473PubMedNIH RePORTER
P30 DK058404NIDDK NIH HHSUnited StatesP30DK058404PubMedNIH RePORTER
U54 MD007587NIMHD NIH HHSUnited StatesU54MD007587PubMedNIH RePORTER
S21 MD000138NIMHD NIH HHSUnited StatesS21MD000138PubMedNIH RePORTER
R25MD007607National Institute on Minority Health and Health Disparities (NIMHD)R25MD007607PubMedNIH RePORTER
MD007587National Institute on Minority Health and Health Disparities (NIMHD)PubMedPubMed
R01 CA190612NCI NIH HHSUnited StatesR01CA190612PubMedNIH RePORTER
I01CX002171U.S. Department of Veterans Affairs (VA)I01CX002171PubMedNIH RePORTER
R25 MD007607NIMHD NIH HHSUnited StatesR25MD007607PubMedNIH RePORTER
U54 CA096297NCI NIH HHSUnited StatesU54CA096297PubMedNIH RePORTER
CA096297/CA096300National Cancer Institute (NCI)PubMedPubMed
S21 MD001830NIMHD NIH HHSUnited StatesS21MD001830PubMedNIH RePORTER
R01CA190612National Cancer Institute (NCI)R01CA190612PubMedNIH RePORTER
S21MD001830National Institute on Minority Health and Health Disparities (NIMHD)S21MD001830PubMedNIH RePORTER
P01CA116087National Cancer Institute (NCI)P01CA116087PubMedNIH RePORTER
P01 CA116087NCI NIH HHSUnited StatesP01CA116087PubMedNIH RePORTER
P01CA028842National Cancer Institute (NCI)P01CA028842PubMedNIH RePORTER
P30CA068485National Cancer Institute (NCI)P30CA068485PubMedNIH RePORTER

See all 25 grantsDownload CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02794428Chemoprevention of Gastric CarcinogenesisResultsYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in42381434Advancing Gastric Cancer Chemoprevention: Early Signals and Ongoing Challenges.https://conductscience.org/library/papers/42381434

Source PubMed

Download CSV of comments and corrections

References57

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130573307High prevalence of non-alcoholic fatty liver disease and metabolic risk factors in Guatemala: A population-based study.Nutr Metab Cardiovasc Dis2019https://conductscience.org/library/papers/30573307PubMed
223403682Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.JAMA2013https://conductscience.org/library/papers/23403682PubMed
31557457Malignant melanoma.Plast Surg Nurs1992https://conductscience.org/library/papers/1557457PubMed
416519678Inhibition of polyamine and spermine oxidases by polyamine analogues.FEBS J2006https://conductscience.org/library/papers/16519678PubMed
524868089At the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer.J Leukoc Biol2014https://conductscience.org/library/papers/24868089PubMed
620600019Polyamines Impair Immunity to Helicobacter pylori by Inhibiting L-Arginine Uptake Required for Nitric Oxide Production.Gastroenterology2010https://conductscience.org/library/papers/20600019PubMed
733688342Gastric Intestinal Metaplasia: Demographic and Epidemiological Characterization in Puerto Rican Hispanics (2012-2014).Gastroenterol Res Pract2021https://conductscience.org/library/papers/33688342PubMed
831484660Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.Cancer Prev Res (Phila)2019https://conductscience.org/library/papers/31484660PubMed
940072512Gastric Cancer Screening in the United States: A Review of Current Evidence, Challenges, and Future Perspectives.Am J Gastroenterol2025https://conductscience.org/library/papers/40072512PubMed
1035785449Racial/ethnic disparities in gastric cancer: A 15-year population-based analysis.Cancer Med2023https://conductscience.org/library/papers/35785449PubMed
112177797414-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.Lancet2011https://conductscience.org/library/papers/21777974PubMed
1215247269Induction of polyamine oxidase 1 by Helicobacter pylori causes macrophage apoptosis by hydrogen peroxide release and mitochondrial membrane depolarization.J Biol Chem2004https://conductscience.org/library/papers/15247269PubMed
1337415099Use of research electronic data capture (REDCap) in a sequential multiple assignment randomized trial (SMART): a practical example of automating double randomization.BMC Med Res Methodol2023https://conductscience.org/library/papers/37415099PubMed
1439614759Evaluating Difluoromethylornithine Safety and Efficacy for Non-Melanoma Skin Cancer Chemoprevention: A Systematic Review.J Cutan Med Surg2025https://conductscience.org/library/papers/39614759PubMed
1538572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
1638033490Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis.Front Oncol2023https://conductscience.org/library/papers/38033490PubMed
1715313165Mouse spermine oxidase: a model of the catalytic cycle and its inhibition by N,N1-bis(2,3-butadienyl)-1,4-butanediamine.Biochem Biophys Res Commun2004https://conductscience.org/library/papers/15313165PubMed
1836493697The nutraceutical electrophile scavenger 2-hydroxybenzylamine (2-HOBA) attenuates gastric cancer development caused by Helicobacter pylori.Biomed Pharmacother2023https://conductscience.org/library/papers/36493697PubMed
1933220252The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions.Gastroenterology2021https://conductscience.org/library/papers/33220252PubMed
2039523394Spermine oxidase promotes Helicobacter pylori-mediated gastric carcinogenesis through acrolein production.Oncogene2025https://conductscience.org/library/papers/39523394PubMed

See all 57 referencesDownload CSV of references

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
EFLORNITHINECHEMBL830Results1https://conductscience.org/library/drugs/CHEMBL830

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Cited by
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41801147

GET https://conductscience.org/api/papers/v1/41801147/grants?page=2